MRI-Guided Multi-Catheter High-Dose-Rate Interstitial Brachytherapy for Uterine Cervical Cancer

被引：0
作者：
Yamazaki, Hideya [1 ]
Masui, Koji [1 ]
Yoshida, Ken [2 ]
Suzuki, Gen [1 ]
Takenaka, Tadashi [1 ]
Yamada, Kei [1 ]
Kotsuma, Tadayuki [2 ]
Takaoka, Yuji [2 ,3 ]
Fujiwara, Kei [2 ]
Tanaka, Yutaka [2 ]
Tanaka, Eiichi [2 ]
机构：
[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Radiol, 465 Kajiicho Kawaramachi Hirokoji,Kamigyo Ku, Kyoto 6028566, Japan
[2] Natl Hosp Org, Osaka Natl Hosp, Dept Radiat Oncol, Osaka 5400006, Japan
[3] Saito Yukoukai Hosp, Dept Radiol, Ibaraki 5670085, Japan
来源：
CANCERS | 2025年 / 17卷 / 05期
关键词：
cervical cancer; MRI-guided brachytherapy; interstitial brachytherapy; EXTERNAL-BEAM RADIOTHERAPY; AMERICAN BRACHYTHERAPY; VOLUME PARAMETERS; PELVIC CONTROL; RECOMMENDATIONS; CARCINOMA; CHEMOTHERAPY; SURVIVAL; TERMS;
D O I：
10.3390/cancers17050770
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Objectives To evaluate the efficacy and safety of unique magnetic resonance imaging (MRI)-guided interstitial brachytherapy (ISBT) for locally advanced cervical cancer that is unsuitable for intracavitary brachytherapy (ICBT) or intracavitary/interstitial brachytherapy (ICISBT). Methods: We analyzed the clinical outcomes, including toxicity, of 68 previously untreated patients with cervical cancer treated between 2014 and 2024. Results: The median high-risk clinical target volume (HR-CTV) was 53.20 cc (range, 16.34-147.03 cc) with ISBT. With a median follow-up time of 37.5 months (7-115 months), the three-year local control, progression-free survival, and overall survival rates were 89.8%, 52.4%, and 70.9%, respectively. Multivariate analyses showed significant associations of histology with local control, overall treatment times, HR-CTV volume with overall survival rate, over all treatment times, and HR-CTV volume and M category with progression-free survival. Toxicity grade 3 occurred in 12 patients (17.6%) and consisted of four genitourinary (5.8%) and seven gastrointestinal (10.2%) toxicities. Conclusions: MRI-guided ISBT is an effective treatment strategy for obtaining a favorable local control rate for selected advanced diseases with an acceptable complication rate. Future research is warranted to elucidate who would be good candidates for MRI-guided ISBT.
引用
收藏
页数：13
相关论文
共 30 条
[1]   Magnetic resonance imaging after external beam radiotherapy and concurrent chemotherapy for locally advanced cervical cancer helps to identify patients at risk of recurrence [J].
Angeles, Martina Aida ;
Baissas, Pauline ;
Leblanc, Eric ;
Lusque, Amelie ;
Ferron, Gwenael ;
Ducassou, Anne ;
Martinez-Gomez, Carlos ;
Querleu, Denis ;
Martinez, Alejandra .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (03) :480-486
[2]   High-dose-rate interstitial brachytherapy for gynecologic malignancies [J].
Beriwal, Sushil ;
Bhatnagar, Ajay ;
Heron, Dwight E. ;
Selvaraj, Raj ;
Mogus, Robert ;
Kim, Hayeon ;
Gerszten, Kristina ;
Kelley, Joseph ;
Edwards, Robert P. .
BRACHYTHERAPY, 2006, 5 (04) :218-222
[3]   Prognostic impact of tumor size reduction assessed by magnetic resonance imaging after radiochemotherapy in patients with locally advanced cervical cancer [J].
Cordoba, Abel ;
Durand, Benedicte ;
Escande, Alexandre ;
Taieb, Sophie ;
Amor, Mariem Ben Haj ;
Le Deley, Marie Cecile ;
Michel, Andree ;
Le Tinier, Florence ;
Hudry, Delphine ;
Martinez, Carlos ;
Leblanc, Eric ;
Becourt, Stephanie ;
Abdedaim, Cyril ;
Bresson, Lucie ;
Lartigau, Eric ;
Mirabel, Xavier ;
Narducci, Fabrice .
FRONTIERS IN ONCOLOGY, 2022, 12
[4]   High dose rate transperineal interstitial brachytherapy for cervical cancer: High pelvic control and low complication rates [J].
Demanes, DJ ;
Rodriguez, RR ;
Bendre, DD ;
Ewing, TL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (01) :105-112
[5]   Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis [J].
Green, JA ;
Kirwan, JM ;
Tierney, JF ;
Symonds, P ;
Fresco, L ;
Collingwood, M ;
Williams, CJ .
LANCET, 2001, 358 (9284) :781-786
[6]   Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group* (I):: concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV [J].
Haie-Meder, C ;
Pötter, R ;
Van Limbergen, E ;
Briot, E ;
De Brabandere, M ;
Dimopoulos, J ;
Dumas, I ;
Hellebust, TP ;
Kirisits, C ;
Lang, SF ;
Muschitz, S ;
Nevinson, J ;
Nulens, A ;
Petrow, P ;
Wachter-Gerstner, N .
RADIOTHERAPY AND ONCOLOGY, 2005, 74 (03) :235-245
[7]   Point-A vs. volume-based brachytherapy for the treatment of cervix cancer: A meta-analysis [J].
Hande, Varsha ;
Chopra, Supriya ;
Kalra, Babusha ;
Abdel-Wahab, May ;
Kannan, Sadhana ;
Tanderup, Kari ;
Grover, Surbhi ;
Zubizarreta, Eduardo ;
Rubio, Jose Alfredo Polo .
RADIOTHERAPY AND ONCOLOGY, 2022, 170 :70-78
[8]   Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].
Kanda, Y. .
BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458
[9]   The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:: Design, application, treatment planning, and dosimetric results [J].
Kirisits, C ;
Lang, S ;
Dimopoulos, J ;
Berger, D ;
Georg, D ;
Pötter, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (02) :624-630
[10]   3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB-IVB Cervical Cancer [J].
Kokabu, Tetsuya ;
Masui, Koji ;
Tarumi, Yosuke ;
Noguchi, Naoki ;
Aoyama, Kohei ;
Kataoka, Hisashi ;
Matsushima, Hiroshi ;
Yoriki, Kaori ;
Shimizu, Daisuke ;
Yamazaki, Hideya ;
Yamada, Kei ;
Mori, Taisuke .
CANCERS, 2022, 14 (05)
123